XML 41 R27.htm IDEA: XBRL DOCUMENT v3.24.3
Equity-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2024
Equity-Based Compensation  
Summary of allocation of equity-based compensation

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

    

2024

    

2023

    

2024

    

2023

Research and development expense

$

4,398

$

2,858

$

11,980

$

8,341

General and administrative expense

 

5,252

 

4,345

 

15,146

 

11,850

$

9,650

$

7,203

$

27,126

$

20,191

Summary of unrecognized equity-based compensation expense

As of September 30, 2024

Unrecognized Expense (in thousands)

    

Weighted Average Remaining Period of Recognition (years)

Restricted Stock Units

$

35,001

2.8

Stock Options

40,456

2.6

$

75,457

Summary of stock activity

Weighted

Average Grant

    

Number of Units

    

Date Fair Value

Restricted stock units as of December 31, 2023

 

2,089,552

$

11.92

Granted

 

2,126,820

$

13.52

Vested

 

(649,559)

$

12.38

Forfeited

 

(179,956)

$

12.42

Restricted stock units as of September 30, 2024

 

3,386,857

$

12.82

Summary of stock option activity

Weighted

Weighted

Average

Number of 

Average

Remaining

Aggregate

    

Shares

    

Exercise Price

    

Contractual Term

    

Intrinsic Value

(in years)

(in thousands)

Outstanding as of December 31, 2023

 

7,300,953

$

15.00

7.90

$

52,299

Granted

 

2,835,756

$

13.52

Exercised

(94,988)

$

5.79

Cancelled

 

(371,557)

$

19.94

Outstanding as of September 30, 2024

 

9,670,164

$

14.47

7.80

$

2,967

Options exercisable as of September 30, 2024

 

4,831,989

$

16.50

6.72

$

2,310

Schedule of weighted average assumptions in fair value

Nine Months Ended

September 30, 

2024

    

2023

Risk-free interest rate

4.09

%  

3.87

%

Expected dividend yield

0.0

%  

0.0

%

Expected term (years to liquidity)

6.00

6.12

Expected volatility

91.15

%  

90.54

%